8-K: Neuraxis Terminates Masimo Agreement, Launches Employee Stock Purchase Plan

Neuraxis, Inc. has terminated its license and collaboration agreement with Masimo Corporation for the NSS-2 Bridge device, regaining full rights to the product, and simultaneously adopted a new Employee Stock Purchase Plan to foster employee ownership.

Summary

• Neuraxis, Inc. entered into a termination agreement with Masimo Corporation on July 1, 2025, to end their License and Collaboration Agreement, originally dated April 9, 2020.
• Under the original agreement, Masimo was granted an exclusive, fully paid-up, royalty-free license to certain patents and trademarks related to the NSS-2 Bridge device, a percutaneous nerve field stimulator for opioid withdrawal symptoms, for which Masimo paid a one-time fee of $250,000.
• As a result of the termination, Neuraxis will pay Masimo $200,000 in cash, in two equal installments of $100,000 each, due on December 31, 2025, and June 30, 2026.
• Neuraxis will no longer receive any licensing payments or other revenue from the NSS-2 Bridge device from Masimo, but regains full rights to the product, the licensed trademark (BRIDGE), and related patents.
• The company's compensation committee adopted the Neuraxis, Inc. 2025 Employee Stock Purchase Plan (ESPP) on July 1, 2025, effective immediately.
• The ESPP allows eligible employees to purchase shares of the company's common stock at a 15% discount using payroll deductions.
• The maximum number of shares that may be issued under the ESPP is 100,000, subject to an annual increase on January 1 of each year from 2026 through 2035 by the lesser of (i) 1% of the company's outstanding capital stock as of the prior December 31 or (ii) 100,000 shares.
• Stockholder approval for the Employee Stock Purchase Plan must be obtained within 12 months of July 1, 2025.

Sentiment

Score: 6

Explanation: While the termination of the Masimo agreement involves an immediate cash outflow and loss of a revenue stream, regaining full rights to the NSS-2 Bridge device offers significant strategic upside for future direct commercialization. The adoption of the new Employee Stock Purchase Plan is a positive development for employee retention and alignment with shareholder interests. The overall sentiment is moderately positive, balancing immediate financial costs with long-term strategic potential.

Positives

• Regaining full control and commercialization rights for the NSS-2 Bridge device, its trademark, and related patents, which allows Neuraxis to pursue new strategic avenues for the product.
• Adoption of the 2025 Employee Stock Purchase Plan, which is designed to enhance employee retention, secure new talent, and align employee interests with shareholder value by offering an ownership stake.
• The ESPP provides a competitive 15% discount on common stock purchases, making it an attractive benefit for eligible employees.

Negatives

• Neuraxis is obligated to pay Masimo Corporation $200,000 in cash, representing a direct cash outflow.
• The company will no longer receive any licensing payments or other revenue from the NSS-2 Bridge device from Masimo.
• Neuraxis now assumes all responsibilities and potential liabilities related to the manufacturing, development, marketing, and sale of the NSS-2 Bridge device post-termination.

Risks

• The Employee Stock Purchase Plan requires stockholder approval within 12 months of July 1, 2025, for its continued operation.
• Assuming full commercialization responsibility for the NSS-2 Bridge device may require significant new investments in marketing, sales, and distribution infrastructure.
• The company is now solely exposed to product liability and product warranty claims for NSS-2 Bridge devices sold after the termination agreement's effective date.
• The company makes no representation to maintain special tax treatment or avoid unfavorable tax treatment for ESPP participants, and its corporate activities will not be constrained by potential negative tax impacts on participants.

Future Outlook

The company will no longer receive licensing payments or other revenue from the NSS-2 Bridge device from Masimo. The adoption of the Employee Stock Purchase Plan is intended to retain and secure new employees, providing incentives for their maximum efforts towards the company's success.

Management Comments

• The purpose of the Employee Stock Purchase Plan is to give eligible employees of the Company an opportunity to acquire an ownership interest in the Company by providing eligible employees the opportunity to purchase shares of the Company’s common stock at a 15% discount using payroll deductions.

Industry Context

The termination of the Masimo agreement suggests a strategic shift for Neuraxis regarding the NSS-2 Bridge device, potentially indicating a move towards direct commercialization or seeking new partnerships within the pain management and opioid withdrawal treatment sector. The adoption of an Employee Stock Purchase Plan is a common and competitive practice in the biotech and medical device industries to attract, retain, and incentivize talent.

Comparison to Industry Standards

• The 15% discount offered in the Employee Stock Purchase Plan is a standard and competitive discount rate for such plans across the medical technology and pharmaceutical industries, comparable to offerings from companies like Medtronic or Abbott Laboratories.
• The mechanism for increasing the ESPP share reserve (lesser of 1% of outstanding shares or a fixed number like 100,000 shares) is a common approach to manage potential dilution while ensuring adequate shares for employee participation, similar to practices at other growth-oriented medical technology firms.
• Regaining full commercialization rights to a licensed product like the NSS-2 Bridge device is a significant strategic move, often pursued by smaller biotech firms aiming to maximize the value of their intellectual property, contrasting with larger entities that might prefer continued licensing arrangements.

Corporate Governance

Stakeholder Impact

• Shareholders: Face an immediate cash outflow and loss of previous licensing revenue, but gain potential long-term value from the company's full control over the NSS-2 Bridge device. There is also potential for dilution from the Employee Stock Purchase Plan.
• Employees: Benefit from the new Employee Stock Purchase Plan, which allows them to purchase company stock at a 15% discount, fostering ownership, retention, and aligning their financial interests with the company's performance.
• Masimo Corporation: Receives a $200,000 payment and is released from all future obligations and claims related to the NSS-2 Bridge license agreement.

Next Steps

• Neuraxis is scheduled to make two $100,000 cash payments to Masimo Corporation by December 31, 2025, and June 30, 2026.
• Neuraxis must obtain stockholder approval for the 2025 Employee Stock Purchase Plan within 12 months of July 1, 2025.
• Neuraxis will assume full responsibility for the commercialization, development, and marketing of the NSS-2 Bridge device.

Key Dates

Recommendation

Keywords

Neuraxis, Masimo, NSS-2 Bridge, License Agreement Termination, Employee Stock Purchase Plan, ESPP, Opioid Withdrawal, PNFS, Corporate Governance, Stock Plan, NRXS